Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-16
1999-06-08
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544408, A61K 3150
Patent
active
059104970
ABSTRACT:
Compounds of the Formula I ##STR1## are inhibitors of the 5.alpha.-reductase 1 isozyme, and are useful alone, or in combination with a 5.alpha.-reductase 2 inhibitor, for the treatment of androgenic sensitive disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, and benign prostatic hyperplasia.
REFERENCES:
patent: 4220775 (1980-09-01), Rasmusson et al.
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 4859681 (1989-08-01), Rasmusson et al.
patent: 5049562 (1991-09-01), Rasmusson et al.
patent: 5084574 (1992-01-01), Bhattacharya et al.
patent: 5116983 (1992-05-01), Bhattacharya et al.
patent: 5120742 (1992-06-01), Rasmusson et al.
patent: 5138063 (1992-08-01), Rasmusson et al.
patent: 5151429 (1992-09-01), Rasmusson et al.
patent: 5215894 (1993-06-01), Arison et al.
patent: 5278159 (1994-01-01), Bakshi et al.
patent: 5359071 (1994-10-01), Durette et al.
patent: 5380728 (1995-01-01), Rasmusson
patent: 5407944 (1995-04-01), Goldman
patent: 5512555 (1996-04-01), Waldstreicher
patent: 5543417 (1996-08-01), Waldstreicher
patent: 5547957 (1996-08-01), Gormley et al.
patent: 5567708 (1996-10-01), Rasmusson et al.
patent: 5571817 (1996-11-01), Rasmusson et al.
patent: 5719158 (1998-02-01), Durette
Helliker, Wall Street Journal, Jun. 7, 1991, at A1, A7, "Alopecia Sufferers Seek to Suffer Less and Not in Silence".
Burger, Medicinal Chemistry, 2nd ed., (1960), p. 42, "Relation of Chemical Structure and Biological Activity".
Stinson, Chem. & Eng. News, pp. 7-8, Jun. 29, 1992, "Prostate Drug Proscar Cleared for Marketing".
Diani et al., J. Clin. Endocrin. & Metab., vol. 74, No. 2, pp. 345-350 (1990), "Hair Growth Effects of Oral Administration of Finasteride, a Steroid 5alpha-Reductase Inhibitor . . . ".
Rasmusson et al., J. Med. Chem., vol. 29, pp. 2298-2315 (1986), "Azasteroids: Structure Activity Relationship of Inhibiting 5alpha-Reductase and of Androgen Receptor Binding".
The Daily (Tuesday, May 7, 1996), "New Data on Proscar, Abbott's Hytrin Show Conflicting Results".
Wall Street Journal (Tuesday, May 7, 1996), "Study Finds Abbott's Prostate Drug is Much More Effective than Merck's", p. B4.
US News & World Report, May 20, 1996, "Zapping a problem prostate".
Boyle, Urology, vol. 48 (1996), pp. 398-405, "Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride . . . ".
Lepor, N. Engl. J. of Med., vol. 335 (1996), pp. 533-539, "The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia".
Walsh, N. Engl. J. of Med., vol. 335 (1996), pp. 585-588, "Treatment of benign prostatic hyperplasia".
Durette Philippe L.
Hagmann William K.
Langen Derek Von
Lanza, Jr. Thomas J.
Rasmusson Gary H.
Daus Donald G.
Fitch Catherine D.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
16-pyrazinyl-substituted-4-aza-androstane 5-.alpha.-reductase is does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 16-pyrazinyl-substituted-4-aza-androstane 5-.alpha.-reductase is, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 16-pyrazinyl-substituted-4-aza-androstane 5-.alpha.-reductase is will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1683439